Patents by Inventor Pritom Shah

Pritom Shah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5585376
    Abstract: The present invention relates to compounds of general formula (I) ##STR1## and physiologically acceptable salts thereof wherein the group NR.sub.1 R.sub.2 represents a 5-7 membered saturated heterocyclic ring which may be substituted by one or two methyl groups; R.sub.3 is C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl or phenyl optionally substituted by 1 or 2 halogen atoms; R.sub.4 is phenyl or phenyl substituted by one or two groups selected from the group consisting of halogen, C.sub.1-4 alkyl, trifluoromethyl, trifluoromethoxy or (CH.sub.2).sub.n R.sub.5 wherein n is zero or 1 and R.sub.5 represents C.sub.1-4 alkoxy, hydroxy, nitro, cyano, CO.sub.2 R.sub.6, S(O).sub.p CH.sub.3, NR.sub.7 R.sub.8, CONR.sub.7 R.sub.8, SO.sub.2 NR.sub.7 CO(C.sub.1-4)alkyl, tetrazolyl, carboxamidotetrazolyl, or a 3-trifluoromethyl 1,2,4-triazolyl; R.sub.6 is hydrogen, C.sub.1-4 alkyl or benzyl; R.sub.7 is hydrogen or C.sub.1-4 alkyl, R.sub.8 is hydrogen, C.sub.1-4 alkyl, SO.sub.2 CH.sub.3 or SO.sub.2 CF.sub.3, X represent hydrogen, C.
    Type: Grant
    Filed: October 30, 1995
    Date of Patent: December 17, 1996
    Assignee: Glaxo Wellcome Inc.
    Inventors: Harry Finch, Pritom Shah, Robin A. E. Carr
  • Patent number: 5569654
    Abstract: Compounds of general formula (I) ##STR1## and physiologically acceptable salts thereof; wherein R.sub.1 represents CH.sub.2 CONR.sub.5 R.sub.6 or CH.sub.2 COR.sub.7 ;R.sub.2 represents a phenyl group optionally substituted by 1 or 2 substituents selected from halogen, alkyl, nitro, cyano, trifluoromethyl, trifluoromethoxy, alkylthio, alkylsulphinyl, alkylsulphonyl, amino, substituted amino, hydroxy, alkoxy, methylenedioxy, alkoxycarbonyl, oxazolyl or oxadiazolyl;A represents a C.sub.1-4 straight or branched alkylene chain;R.sub.3 and R.sub.4 independently represent hydrogen or C.sub.1-4 alkyl or R.sub.3 and R.sub.4 together with the nitrogen atom to which they are attached form a saturated 5-7 membered heterocyclic ring, which ring may contain an additional heteroatom selected from oxygen, sulphur or nitrogen;R.sub.5 represents hydrogen or C.sub.1-4 alkyl;R.sub.6 represents C.sub.1-4 alkyl or phenyl, optionally substituted by halogen, or R.sub.5 and R.sub.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: October 29, 1996
    Assignee: Glaxo Group Limited
    Inventors: Duncan R. Armour, Philip C. Box, Pritom Shah
  • Patent number: 5389659
    Abstract: The invention provides compounds of the general formula (I): ##STR1## or a physiologically acceptable salt, solvate (e.g. hydrate) or a metabolically labile ester thereof.The compounds may be used in the treatment or prophylaxis of hypertension and diseases associated with cognitive disorders.
    Type: Grant
    Filed: March 8, 1991
    Date of Patent: February 14, 1995
    Assignee: Glaxo Group Limited
    Inventors: Barry C. Ross, David Middlemiss, Colin D. Eldred, John G. Montana, Pritom Shah
  • Patent number: 5252593
    Abstract: The invention provides compounds of formula (I): ##STR1## or a physiologically acceptable salt, solvate or metabolically labile ester thereof.The compounds may be used in the treatment or prophylaxis of hypertension and diseases associated with cognitive disorders.
    Type: Grant
    Filed: May 15, 1992
    Date of Patent: October 12, 1993
    Assignee: Glaxo Group Limited
    Inventors: Barry C. Ross, David Middlemiss, David I. C. Scopes, Torquil I. M. Jack, Kevin S. Cardwell, Michael D. Dowle, Colin D. Eldred, John G. Montana, Pritom Shah, Stephen P. Watson